Intravitreal injection of anti‐VEGF drugs has also been widely performed as a standard of care for diabetic retinopathies such as diabetic macular edema and PDR.[7, 9] However, targeting VEGF alone has several limitations. The gene discussed is VEGFA; the disease is diabetic macular edema.